| Â | Case number | Preconditioning | GVHD prophylaxis | Neutrophil engraftment | Increase of CD19+ and Ig | Reference |
|---|
Howard et al. |
N = 1 | (−) | (−) | No | No | [6] |
N = 3 | (−) | CsA/MMF | No | No | [6] |
Abu-Arja et al. |
N = 1 | ETP/CY/12Gy | TAC/MTX | Yes | Yes | [7] |
Ikegame et al. |
N = 1 | FLU/CY/ATG/3Gy | CsA/MMF | Yes | Yes | This report |
- There are two English reports of allo-SCT for XLA. Howard et al. present six cases based on their experience, three of which underwent SCT without preconditioning or GVHD prophylaxis, while the other three underwent GVHD prophylaxis consisting of cyclosporine and mycophenolate mofetil (CsA/MMF). No patients achieved donor engraftment or increases in CD19+ cell numbers or immunoglobulin (Ig) levels [6]. Abu-Arja et al. reported successful allo-SCT in a patient with XLA and AML, in which they used a myeloablative conditioning regimen consisting of etoposide 40Â mg/kg for 1Â day, cyclophosphamide (CY) 60Â mg/kg/day, and 12Â Gy of total body irradiation (ETP/CY/12Gy), and GVHD prophylaxis consisting of tacrolimus and methotrexate (TAC/MTX). The patient achieved engraftment with donor chimerism and had normal CD19+ cell numbers and Ig levels. In our case, the preconditioning regimen used comprised fludarabine, CY, rabbit anti-thymocyte globulin, and 3Â Gy of TBI (FLU/CY/ATG/3Gy), and GVHD prophylaxis was CsA and MMF (CsA/MMF). As described in the text, the patient achieved engraftment with donor chimerism, with a rapid increase in CD19+ cell numbers and the production of Ig. To the best of our knowledge, this is the first English case report of successful allo-SCT for XLA
